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Abstract
The development of new drugs against Chagas disease is a priority since the currently available medicines have toxic
effects, partial efficacy and are targeted against the acute phase of disease. At present, there is no drug to treat the chronic
stage. In this study, we have optimized a whole cell-based assay for high throughput screening of compounds that inhibit
infection of mammalian cells by Trypanosoma cruzi trypomastigotes. A 2000-compound chemical library was screened using
a recombinant T. cruzi (Tulahuen strain) expressing b-galactosidase. Three hits were selected for their high activity against T.
cruzi and low toxicity to host cells in vitro: PCH1, NT1 and CX1 (IC50: 54, 190 and 23 nM, respectively). Each of these three
compounds presents a different mechanism of action on intracellular proliferation of T. cruzi amastigotes. CX1 shows strong
trypanocidal activity, an essential characteristic for the development of drugs against the chronic stage of Chagas disease
where parasites are found intracellular in a quiescent stage. NT1 has a trypanostatic effect, while PCH1 affects parasite
division. The three compounds also show high activity against intracellular T. cruzi from the Y strain and against the related
kinetoplastid species Leishmania major and L. amazonensis. Characterization of the anti–T. cruzi activity of molecules
chemically related to the three library hits allowed the selection of two compounds with IC50 values of 2 nM (PCH6 and
CX2). These values are approximately 100 times lower than those of the medicines used in patients against T. cruzi. These
results provide new candidate molecules for the development of treatments against Chagas disease and leishmaniasis.
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Introduction
Chagas disease or American trypanosomiasis is a devastating
disease caused by the trypanosomatid protozoan Trypanosoma cruzi.
It is endemic in 18 countries of Central and South America,
putting 120 million of people at risk, with an estimated 16–18
million people currently infected [1]. The disease first manifests
itself with an acute phase involving symptoms of swelling near the
infection site, fever, fatigue, and enlarged lymphatic organs. It can
then remain asymptomatic or manifest itself in a chronic form
leading to cardiac insufficiency and megacolon. The two available
drugs used to fight T. cruzi parasites during the acute stage are
benznidazole (BZN) (Rochagan, Hoffmann-LaRoche) and nifurti-
mox (Lampit, Bayer). These drugs have toxic side effects and are
not always effective. There is no drug available to treat the chronic
stage of Chagas disease. Though some studies suggest that
treatment with either BZN or nifurtimox decreases parasite load
and slows disease progression, treatment of the chronic stage with
these compounds is not officially recommended [2].
T. cruzi cases predominate in South America, but as migrant
numbers increase in the USA, Canada and Europe, Chagas
disease becomes a more widely spread public health problem,
especially because BZN and nifurtimox are not approved by the
countries’ respective regulatory agencies and disease can be
transmitted by contaminated blood donations. A need for
development of new anti-T. cruzi compounds targeting the acute
and/or chronic stages of the disease is therefore urgent.
The T. cruzi life cycle requires both an insect and a mammalian
host. In the latter, the parasite development involves two stages:
the amastigote form (intracellular parasites actively dividing within
the cytoplasm of infected cells) and the trypomastigote form (free
motile parasites that are released upon cell rupture into the blood
and are able to infect cells) [3]. Compounds with curative
properties will be efficient if they target either free trypomastigotes
to inhibit the re-invasion of new cells, or intracellularly dividing
amastigotes to prevent the release of new infective parasites.
Leishmania is a kinetoplastid parasite releated to T. cruzi and the
causative agent of leishmaniasis, a disease whose manifestations in
humans range from mild cutaneous and mucocutaneous lesions to
fatal visceral infections. Among the many species responsible for
cutaneous leishmaniasis, L. major of the Old World, is prevalent in
Europe, Asia and Africa and L. amazonensis of the New World,
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America. These two species diverged from each other 40–80
million years ago, leading to significant differences in host-parasite
interactions and hence response to drugs [4]. Human infection
initiates with the bite of a sandfly that deposits non-dividing
metacyclic promastigotes into the host skin. The parasites are then
taken up by professional phagocytes, differentiate to obligate
intracellular amastigotes and multiply within an acidified phago-
lysosome, known as the parasitophorous vacuole. They eventually
rupture the cell and spread further to uninfected cells. Therefore
effective drugs should target the intravacuolar dividing parasites.
Pentavalent antimony is still widely used to treat leishmaniasis, but
drug resistance has appeared. Currently, the efficacy of liposomal
Amphotericin B injected in mono- and combination therapies is
being evaluated [5] and has displayed 90% of cure rates in
combination with oral Miltefosine for visceral disease [6].
However, some cutaneous leishmaniasis are refractory and other
drug treatments have 50% cure rates.
Screening libraries of chemical compounds against a standard-
ized highly reproducible simple assay, or high throughput
screening (HTS), offers an important tool in accelerating the
discovery of new leads against parasitic diseases. This strategy’s
rationale is based on the assumption that screening of molecules
with drug-like properties and highly diverse three-dimensional
structures could allow the discovery of attractive new targets.
A transgenic T. cruzi strain expressing the reporter enzyme b-
galactosidase (b-gal), also named LacZ, from Escherichia coli has
been engineered by Buckner et al. [7]. This strain allows simple
detection of parasite growth by measuring the b-gal activity, which
correlates with parasite numbers. Other parasites expressing b-gal,
such as Toxoplasma gondii, have been effectively used for screening
compounds [8,9]. The T. cruzi b-gal strain induces severe
pathology in vivo [10], and it has been shown to grow in vitro
similarly to control strains [7]. Beta-Gal T. cruzi were successfully
used to screen compounds for activity against T. cruzi epimasti-
gotes, which is the form found in the intestine of the insect host
[11]. Compounds active against Leishmania mexicana and Trypano-
soma brucei were also tested both on intracellularly replicating T.
cruzi b-gal parasites and on contaminated blood [7].
In this study, we have optimized a whole-cell-based assay
for HTS using the T. cruzi b-gal strain and screened a
2000-compound library to discover new molecules with activity
against T. cruzi. We identified three compounds which inhibit
intracellular replication of amastigotes in the nanomolar range and
low toxicity on mammalian cells.
Methods
Parasite and mammalian cells
LLC-MK2 and NIH/3T3 cells were cultivated in DMEM
supplemented with 10% FBS, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, and 0.292 mg/ml glutamine (Pen-Strep-Glut).
T. cruzi parasites from the Tulahuen strain stably expressing the
b-gal gene (clone C4) [7] and from the Y strain were maintained in
culture by infection of LLC-MK2 or NIH/3T3 cells every 5 or
6 days in DMEM with 2% FBS and 1% Pen-Strep-Glut. Bone
marrow-derived macrophages were prepared from femurs of
BALB/c mice (Taconic) and cultured for 7 days in DMEM
supplemented with 10% FBS, Pen-Strep-Glut and 30% (v/v) L
cell-conditioned medium as a source of CSF-1.
Trypomastigotes were obtained from the supernatant of
infected cultures harvested between days 5 and 7. To remove
amastigotes, trypomastigotes were allowed to swim out of the
pellet of samples that had been centrifuged for 7 min at 2500 rpm.
L. major strain Friedlin V1 (MHOM/JL/80/Friedlin) promasti-
gotes were grown in medium M199 as previously described [12],
and infective-stage metacyclic promastigotes were isolated from
stationary 5-day old cultures by density centrifugation on a Ficoll
gradient [13]. L. amazonensis IFLA/BR/67/PH8 strain promasti-
gotes were maintained in vitro as previously described [14]. All cells
and parasites were cultivated at 37uC in an incubator containing
5% CO2 and 95% air humidity, unless specified otherwise.
T. cruzi growth inhibition assay
NIH/3T3 cells and parasites were harvested, washed once and
resuspended in DMEM supplemented with 2% FBS and Pen-
Strep-Glut. DMEM did not contain phenol red to avoid
interference with the assay absorbance readings at 590 nM.
Different numbers of NIH/3T3 cells were seeded in 96-well plates.
After 3 h, compounds were added at the indicated concentrations
and mixed by pipetting. BZN tablets (Rochagan, Roche) dissolved
in DMSO and 4 mM Amphotericin B solution (Sigma-Aldrich)
were used as positive controls. Different numbers of T. cruzi
parasites were added in a final volume of 200 ml/well. After
4 days, 50 ml of PBS containing 0.5% of the detergent NP40 and
100 mM Chlorophenol Red-b-D-galactoside (CPRG) (Fluka) were
added. Plates were incubated at 37uC for 4 h and absorbance was
read at 590 nm using a Tecan Spectra Mini plate reader.
To calculate the Z9 factor, we used the formula described by
Zhang et al. [15]: Z9=12[(3sc++3sc2)/| mc+2mc2|] where
sc+=standard deviation (SD) of positive control, sc2=SD of
negative control, mc+=mean of positive control, mc2=mean of
negative control. Subsequently, the best ratio was used for all
growth inhibition assays (50.000 cells and parasites, multiplicity of
infection (MOI) 1:1).
To determine IC50 values, b-gal activity (Abs590) was plotted
against compound concentration for each compound. The IC50
was determined as the concentration at which the activity
(absorbance) was half that in the absence of compound. Mean
IC50 values are the average of independent experiments performed
in triplicate on three different days.
Chemical library and screen protocol
Two thousand compounds in dimethyl sulfoxide (DMSO) from
the DIVERSet library (ChemBridge Corporation, San Diego, CA)
Author Summary
Chagas disease is caused by infection with the protozoan
parasite Trypanosoma cruzi and affects 16 million people in
South and Central America. The disease starts with an
acute phase where the parasite replicates rapidly and, if it
remains untreated, is followed by a chronic phase, which
can induce severe pathologies including cardiac insuffi-
ciency and megacolon, leading to death. Only two drugs
with high toxicity exist to treat the acute phase of the
disease and no drug is available for treatment of the
chronic stage. We have screened a chemical library
containing 2000 compounds to find molecules that inhibit
the infection of host cells by T. cruzi in vitro. We found
three different families of compounds that inhibit the
parasite infection very efficiently, with low toxicity to host
cells in vitro. We found that two of the compounds inhibit
replication of the parasites, but the third one induces
complete disintegration of the parasites inside host cells.
This is especially interesting for the development of new
drugs against the chronic stage of the disease, where
parasites are intracellular and do not replicate actively.
Compounds Active against Trypanosoma cruzi
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Each plate also contained triplicate wells of negative control (no
compounds), positive control (4 mM Amphotericin B) and 1% DMSO
(vehicle). Selected hits among the screened compounds include N9-
{[5-(2,3-dichlorophenyl)-2-furyl]methylene}-2-pyridinecarbohydrazide
(hydrazide 1; PCH1), 2-(3-nitro-1H-1,2,4-triazol-1-yl)-N-{3-nitro-5-
[3-(trifluoromethyl)phenoxy]phenyl}acetamide (nitrotriazole 1; NT1)
and 1-[6-(4-chloro-3,5-dimethylphenoxy)hexyl]-1H-imidazole (chloro-
xylenol 1; CX1).
Chemically related compounds were also ordered from
ChemBridge Corporation and include N9-{[5-(2,3-dichlorophenyl)-
2-furyl]methylene}nicotinohydrazide (PCH2), N9-{[5-(2,3-
dichlorophenyl)-2-furyl]methylene}isonicotinohydrazide (PCH3),
4-bromo-N9-{[5-(2,3-dichlorophenyl)-2-furyl]methylene}benzohy-
drazide (PCH4), N9-{[5-(3-chlorophenyl)-2-furyl]methylene}
-2-pyridinecarbohydrazide (PCH5), N9-{[5-(2-chlorophenyl)-2-
furyl]methylene}-2-pyridinecarbohydrazide (PCH6), N9-{[5-
(3,4-dichlorophenyl)-2-furyl]methylene}-2-pyridinecarbohydrazide
(PCH7), N9-{[5-(3-chloro-4-methoxyphenyl)-2-furyl]methylene}-
2-pyridinecarbohydrazide (PCH8), N9-{[5-(2,5-dichlorophenyl)-
2-furyl]methylene}benzohydrazide (PCH9), N9-{[5-(2-chlorophe-
nyl)-2-furyl]methylene}nicotinohydrazide (PCH10), N-(3-methoxy
-5-nitrophenyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (NT2),
N-[3-nitro-5-(3-pyridinyloxy)phenyl]-2-(3-nitro-1H-1,2,4-triazol-1-yl)
acetamide (NT3), N-{3-[(5-chloro-3-pyridinyl)oxy]-5-nitrophe-
nyl}-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (NT4), 2-(3-nitro-
1H-1,2,4-triazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide (NT5),
N-[2-chloro-5-(trifluoromethyl)phenyl]-2-(3-nitro-1H-1,2,4-triazol-
1-yl)acetamide (NT6), N-[4-chloro-2-(trifluoromethyl)phenyl]-2-
(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (NT7), N-[2-chloro-5-
(trifluoromethyl)phenyl]-4-(3-nitro-1H-1,2,4-triazol-1-yl)butanamide
(NT8), 4-(3-nitro-1H-1,2,4-triazol-1-yl)-N-[2-(trifluoromethyl)phenyl]-
butanamide (NT9), 1-[5-(4-chloro-3,5-dimethylphenoxy)pentyl]-1H
-imidazole (CX2), 1-[4-(4-chloro-3,5-dimethylphenoxy)butyl]-1H-
imidazole (CX3), 1-[6-(4-chloro-2,6-dimethylphenoxy)hexyl]-1H
-imidazole (CX4), 1-[5-(4-chloro-2,6-dimethylphenoxy)pentyl]-1H-
imidazole (CX5) and 1-[4-(4-chloro-2,6-dimethylphenoxy)butyl]-1H-
imidazole (CX6). The derivatives PCH2–PCH10 were chosen with
.80%similarity toPCH1,NT2–NT9 with .85% similarity to NT1
and CX2–CX6 with .90% similarity to CX1.
T. cruzi lysis assay
Trypomastigotes were rinsed once and plated in 96-well plates
at 100,000/well with the compounds in a final volume of 200 mlo f
DMEM without phenol red supplemented with 2% FBS, Pen-
Strep-Glut and 100 mM CPRG. Plates were incubated for 24 h at
37uC and absorbance was read at 590 nm.
Cytotoxicity assay
Cells (NIH/3T3 or HepG2) were washed and plated at a
density of 50,000 cells/well of 96-well plates in 200 ml and allowed
to adhere for 3 h. Twenty-four hour assays were done in DMEM
without phenol red supplemented with 10% FBS and Pen-Strep-
Glut, while 4-day assays were done in the same medium
containing 2% FBS. Drugs were added and mixed. After 1 or
4 days, 20 ml of Alamar Blue (Biosource, Invitrogen) was added.
Plates were incubated for 4 h (HepG2) or 6 h (NIH/3T3) at 37uC
and fluorescence was read using a Labsystems Fluoroskan II plate
reader (excitation: 544 nm, emission: 590 nm) .
To determine TC50 values, fluorescence was plotted against
inhibitor concentration. TC50 was determined as the concentra-
tion at which cytotoxicity (fluorescence) was half that in the
absence of inhibitor.
Invasion and development assays
Fifty thousand NIH/3T3 cells were seeded on sterile glass
coverslips in 12-well plates and allowed to adhere overnight. Five
million parasites were added (MOI 100:1) and allowed to infect for
2 h in DMEM+2% FBS and Pen-Strep-Glut. Parasites were rinsed
out three times with PBS. Infected cells were further incubated
and fixed for 15 min with 4% paraformaldehyde at the times
indicated.
Immunofluorescence assay
Fixed cells on coverslips were rinsed with PBS, permeabilized
for 15 min in PBS with 0.1% Triton X-100 (Sigma-Aldrich). After
blocking for 20 min in PBS with 10% goat serum, 1% bovine
serum albumin, 100 mM glycine and 0.05% sodium azide, cells
were incubated for 1 h at room temperature with a polyclonal
rabbit anti-T. cruzi (gift from Dr B. Burleigh, Harvard School of
Public Health, Boston, MA) at 1:2000 dilution. After rinsing, an
Alexa FluorH 488 goat anti-rabbit IgG secondary antibody
(Molecular Probes, Invitrogen) was added for 1 h at a 1:800
dilution. DNA was stained with DAPI and coverslips were
Figure 1. Screening steps statistics and distribution of
compounds. A. Schematics of the screening steps with number of
compounds and percentage of total compounds at each step. B.
Distribution of relative b-gal activity values of the 2000 compounds
(after normalization to the median of each assay plate). The line shows
the hit selection cutoff (as the average of the normalized hit threshold
per plate).
doi:10.1371/journal.pntd.0000384.g001
Compounds Active against Trypanosoma cruzi
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infected cell, between 200 and 300 infected cells per coverslip were
scored in triplicate samples using an inverted Olympus IX70
microscope with a 606 oil objective. Data are presented as
mean6standard deviation. Images were taken with the same
microscope.
Leishmania growth inhibition assay
Adherent bone marrow-derived macrophages were harvested in
cold DMEM+0.5 mM EDTA and seeded into an 8-well Lab-Tek
II chambered coverglass (Nalge Nunc International, Naperville,
IL) at a concentration of 50,000 cells/chamber 24 h before being
used for infections.
L. major and L. amazonensis parasites were opsonized for 30 min
by incubation in DMEM containing 4% BALB/c serum and then
allowed to invade macrophages in 200 ml DMEM supplemented
with 10% FBS and Pen-Strep-Glut, at a MOI of 3 parasites per
macrophage for 2 h at 33 ˚C (5% CO2, 95% air humidity) [16,17].
Thereafter, non-phagocytosed parasites were washed off, and the
cultures were further incubated in 300 ml of medium in the
presence or the absence of drugs at the indicated concentration for
3 days for L. amazonensis and 5 days for L. major. Medium was
changed and drugs were added again at the same concentration on
day 2 post-infection. Intracellular parasites were assessed after
staining with DAPI (3 mM) by fluorescence microscopy. The total
number of amastigotes/500 macrophages was counted in each
well. Kruskal-Wallis test was used to analyze the data, followed by
a Dunn’s post-comparison test.
Results
Optimization of a 4-day assay for screening
Our first goal was to optimize a simple and reliable assay for
HTS in 96-well format to quantify T. cruzi trypomastigotes’
infection of host cells. This type of assay would allow for the
identification of compounds that inhibit either free extracellular
trypomastigotes or intracellularly dividing amastigotes. The
primary protocol for b-gal-expressing T. cruzi trypomastigotes of
the Tulahuen strain infecting NIH/3T3 cells [7] was modified to
shorten the incubation time of the assay. This is an important
parameter because short incubation times decrease medium
evaporation and lessen concerns about compound stability.
The Z9 factor is a statistical parameter used to assess the
reproducibility and quality of HTS assays by taking into account
the signal dynamic range and the data variation [15]. Assays with
Z9 factors between 0.5 and 1 are considered appropriate for HTS.
To determine which parasite:cell ratio was required to shorten the
incubation time, different concentrations of host cells (NIH/3T3)
and trypomastigotes were tested with or without the well-
characterized anti-trypanosomal compound Amphotericin B. It
was found that 50,000 host cells and 50,000 parasites per well
incubated for 4 days yielded a high and reproducible signal. The
mean Z9 factor of independent experiments performed in
sextuplicate on three different days was 0.834 (60.018).
Screening of a 2000-compound library
To discover new compounds with anti-T. cruzi activity, a library
of 2000 compounds (DIVERSet from Chembridge Corporation)
was screened, initially at 25 mg/ml in single wells. This library
contains compounds from a larger library (EXPRESS-Pick
Collection) that are chosen for maximum pharmacophore
diversity based on 3D conformation and drug-like properties.
We hypothesized that adding test compounds to cells at the same
time than parasites would allow the detection of compounds with
both anti-free trypomastigotes and anti-intracellular growth
activities. Primary screen concentration was 25 mg/ml, which
corresponds to a range of 42 to 112 mM, based on molecular
weights from 223 to 587. The threshold for selecting hits was set as
Figure 2. Three selected hits: chemical names, abbreviations and molecular structures.
doi:10.1371/journal.pntd.0000384.g002
Compounds Active against Trypanosoma cruzi
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times the standard deviation. The screening steps are schemati-
cally illustrated in Fig. 1A. Eighty-four primary hits were obtained
out of the 2000 compounds, as displayed in Fig. 1B, which
represents the distribution of the normalized absorbance readings
of the 2000 compounds. After retesting in exactly the same
conditions, 70 hits were confirmed (3.5% of the total) (data not
shown).
Selection of hits
Our next goal was to select amongst the 70 confirmed hits the
best candidates for further investigation. To this aim, compounds
with high anti-trypanosomal efficacy and low toxicity to host cells
were selected. The anti-trypanosomal activity of the 70 confirmed
hits was first tested at six different concentrations from 25 mg/ml
(51–110 mM depending on compound molecular weight) to 8 ng/
ml (16–35 nM). In parallel, the toxicity of these compounds was
Figure 3. Dose-response curves of selected hits and cytotoxicity on NIH/3T3 cells. A. PCH1;B .NT1 and C. CX1. Each compound was
tested for T. cruzi growth inhibition (black curves, left axis). 50.000 NIH/3T3 cells were incubated with 50.000 b-gal T. cruzi parasites per well in the
presence of each compound and b-gal activity was assayed at 4 days. Cytotoxicity of each compound on NIH/3T3 cells was also assayed (grey curve,
right axis), by incubating 50.000 cells in the presence of compounds. Viability was assayed by incubating cells on day 4 with Alamar Blue for 6 h and
measuring fluorescence. Data are displayed as the mean6standard deviation of triplicate wells from one of three independent experiments.
doi:10.1371/journal.pntd.0000384.g003
Compounds Active against Trypanosoma cruzi
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cells using Alamar Blue (data not shown). Fifty-nine of the 70 hits
lost completely their activity at 5 mg/ml and were discarded.
Out of the 11 remaining hits, three compounds with the highest
anti-trypanosomal activity and low toxicity levels were selected for
further characterization: PCH1: N9-{[5-(2,3-dichlorophenyl)-2-
furyl]methylene}-2-pyridinecarbohydrazide; NT1: 2-(3-nitro-1H-
1,2,4-triazol-1-yl)-N-{3-nitro-5-[3-(trifluoromethyl)phenoxy]phe-
nyl}acetamide; CX1: 1-[6-(4-chloro-3,5-dimethylphenoxy)hexyl]-
1H-imidazole (Fig. 2). These three compounds have at least 50-
fold higher toxicity levels (TC50) versus anti-trypanosomal activity
(IC50). The eight other hits that retained activity at 5 mg/ml
(described in Fig. S1) were not investigated further because of their
low activity and/or high toxicity.
Precise IC50 and TC50 values of the selected hits were calculated
from dose-response curves (Fig. 3). The mean IC50 values (Table 1)
of all three compounds are lower than 1 mM, with compounds
PCH1 and CX1 having IC50 values in the low nanomolar range
(54 and 23 nM, respectively). Under these assay conditions, the
IC50 of BZN was found to be 1.15 mM60.08 (data not shown),
consistent with the value of 1.5 mM reported by Buckner et al. [7].
To characterize the toxicity profiles of the three compounds
further, cytotoxicity assays were performed with HepG2 cells, a
human hepatoma cell line commonly used for in vitro testing of
toxicity [18]. Cells were incubated with compounds for 24 h or
4d a y s .M e a nT C 50 values are displayed in Table 1. The ratio of
TC50 to IC50 was again over 500 at both time points tested for PCH1
and CX1.T h eT C 50 of NT1 was more than 150-fold greater than its
IC50 at 1 day, but decreased to only 40-fold at 4 days.
Mechanism of action of the selected compounds
Our next goal was to determine which stage of parasite
development was inhibited by these compounds. To assess if the
observed effect of compounds was due to direct lysis of free
trypomastigotes before they even invaded cells, we performed a
lysis assay in which 100,000 parasites were incubated for 24 h in
the presence of increasing concentrations of the selected
compounds and the b-gal substrate CPRG. In this assay, b-gal
activity increases proportionally to the number of parasites that are
lysed by the compound, releasing b-gal in the medium. The IC50
was in the micromolar range for all compounds as shown in
Table 1, suggesting that the mechanism of the inhibition observed
during infection of host cells was not due to a direct effect of the
compounds on free trypomastigotes.
We next investigated which stage of host cell infection by T. cruzi
trypomastigotes was inhibited by each of the compounds. To analyze
the effect of the compounds in host cell invasion, we incubated NIH/
3T3 cells for 2 h with trypomastigotes at the IC100 concentration.
After thorough rinsing, fixation and staining of parasites, we did not
find any significant difference with controls (data not shown).
Next, we assessed if compounds were interfering with
intracellular proliferation of amastigotes within mammalian cells.
We infected cells for 2 h, rinsed away the remaining free
trypomastigotes and, after adding the compounds at the IC100
concentrations, we incubated cells for 2–3 days to allow for
amastigote proliferation. In control cells, amastigotes homogenous
in size were distributed throughout the cytoplasm of the host cells
and kinetoplasts were observed closely apposed to the nucleus of
parasites (Fig. 4A at 2 days and Fig. 4B at 3 days).
Upon treatment with PCH1, the morphology of parasites was
severely affected (Fig. 4C). We observed larger amastigotes
containing multiple nuclei and kinetoplasts, which were disorga-
nized and had lost their normal 3-dimensional relationship. These
results suggest that PCH1 induces a defect in cell division.
Treatment with NT1 resulted in infected cells containing only a
few amastigotes of average size with apparently normal nucleus and
kinetoplast (Fig. 4D), suggesting that this compound interferes with
proliferation of amastigotes without affecting their morphology.
CX1 induced parasite death, as observed by the decrease of
structures clearly identifiable as amastigotes. Parasite proteins and
DNA were observed all throughout the cytoplasm, suggesting that
amastigotes were lysed. Moreover, the nucleus of the host cell
containing parasites debris was often pyknotic, suggesting that
death of the parasite was inducing death of the host cell (Fig. 4E).
We also quantified the number of parasites per infected cell,
confirming that both PCH1 and NT1 induced a growth arrest of
intracellular T. cruzi (Fig. 5). In cultures treated with these
compounds, the majority of infected cells contain only one or two
parasites while in control cultures the majority of cells contain 4 or
more parasites. The number of parasites per infected cell could no
be quantified after treatment with CX1 because no parasite
structures were clearly visible. Of note, presence of multiple
parasites within a cell can denote either amastigotes that have
divided or a cell that has been infected by several trypomastigotes.
When the compounds were added 2 days after infection, similar
phenotypes were observed: PCH1 induced major defects in cell
division at the IC100 and parasite lysis at higher doses. NT1 had a
trypanostatic effect. CX1 induced parasite lysis and host cell
apoptosis in concentrations as low as 90 nM (data not shown).
Effect of PCH1, NT1 and CX1 on T. cruzi Y strain
We also confirmed the effect of PCH1, NT1 and CX1 on the
infection by T. cruzi trypomastigotes of the Y strain. We performed
the same development assay and quantified the number of parasites
per infected cell for PCH1 (Fig. 6A) and NT1 ( F i g .6 B ) .A sd e s c r i b e d
above for the Tulahuen strain, CX1 induced parasite lysis with
morphological changes that prevented this type of quantification.
Effect of compounds on growth of L. major and L.
amazonensis in macrophages
To evaluate the effect of these three compounds on another
intracellular kinetoplastid, we tested them against L. major and L.
amazonensis parasites. In the vertebrate host, Leishmania parasites
are intracellular and reside mostly within macrophages inside
phagolysosomes. Therefore, we added a range of compound
concentrations 2 h post-infection of macrophages with metacyclic
promastigotes. A high dose of Amphotericin B (1 mM) was used as
a positive control (IC50=0.1 mM, [19]). Five days post-infection
Table 1. IC50 and TC50 of selected hits.
PCH1 NT1 CX1
IC50 Intracellular growth 54610 nM 190640 nM 2367n M
TC50 NIH/3T3 cells at 4 days .300 mM1 4 66 mM1 6 66 mM
*.55006 *746 *6906
TC50 HepG2 cells at 24 h .300 mM3 0 610 mM5 7 68 mM
*.55006 *1606 *24006
TC50 HepG2 cells at 4 days 6667 mM7 . 6 60.3 mM1 2 64 mM
*12006 *406 *5306
IC50 Free trypomastigotes 240660 mM6 . 8 60.9 mM 13.561.0 mM
*Ratio of TC50 to IC50. Data are displayed as mean6SD of three independent
experiments performed in triplicate.
doi:10.1371/journal.pntd.0000384.t001
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observed a reduction in the number of intracellular parasites with
the three compounds (Fig. 7A). We observed a reduction in
parasite burden at the highest chemical concentration (2 mM) of
about 50% for PCH1, 80% for NCT1 (p,0.05), and 70% for
CX1 (p,0.05). To evaluate the effect of these compounds on
intracellular L. amazonensis, which resides in large communal
phagolysosomes, we repeated this experiment by adding a range of
concentrations 2 h post-infection of macrophages for 3 days
(Fig. 7B). The number of intracellular L. amazonensis parasites
decreased in presence of each of the 3 compounds, reducing the
parasite burden by 70% for PCH1 (p,0.5), 50% for NCT1
(p,0.5), and 70% for CX1 (p,0.5) at 2 mM.
Effect of chemically related compounds on T. cruzi
To assess if chemical modification of the compounds would
improve their inhibitory effect on T. cruzi parasite growth and help
us identify which parts of the molecules are important for their
activity, we tested the activity of compounds chemically related to
PCH1, NT1 and CX1 that were commercially available. These
compounds were identified using the hit2lead website (https://
www.hit2lead.com) and tested for activity against T. cruzi
trypomastigote infection. The IC50 values for these compounds
were determined and compared to their parental compounds
(Fig. 8). We found that, while some of the chemical modifications
caused a decrease of anti-trypanosomal activity, others resulted in
increased efficacy. Interestingly, we found three compounds,
Figure 4. Compounds PCH1, NT1 and CX1 affect the morphology of intracellularly growing T. cruzi. Compounds were added after cells
had been infected for 2 h and extracellular b-gal T. cruzi parasites had been removed by washing. Cells were fixed after 2 or 3 days, stained with an
anti-T. cruzi antibody and DAPI to visualize DNA. Insets show a higher magnification of the parasite nucleus and kinetoplast. In control at 2 days
(panel A) and at 3 days (panel B), multiple amastigotes homogenous in size and shape could be observed throughout the cytoplasm of infected cells.
Upon treatment with 100 nM PCH1 (panel C), larger amastigotes containing multiple disorganized nuclei and kinetoplasts were observed
(arrowheads). Treatment with NT1 at 400 nM (panel D) inhibited replication of parasites without altering their overall morphology. Cells treated with
CX1 at 90 nM (panel E) displayed pycnotic nuclei (star) and debris of parasites protein and DNA throughout the cytoplasm. Scale bar: 5 microns.
doi:10.1371/journal.pntd.0000384.g004
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compared to their parental structures, with IC50 values of 2.1,
2.5 and 5.1 nM respectively (TC50 values of PCH6 and CX2 are
18.5 and 19.5 mM, respectively).
More specifically, for PCH1, the pyridine nitrogen was varied
from ortho (PCH1)t ometa (PCH2) and para (PCH3) positions,
resulting in 35-fold and .200-fold increases in IC50, respectively.
Substitution of the pyridine ring with a para-bromophenyl group as
in PCH4 also abolished activity, further reinforcing the impor-
tance of an ortho-nitrogen within the ring. Modifications to the
chlorophenyl group explored the role of chloride substituents on
this ring. Removal of the chloride at the ortho position as in PCH5
did not alter the effect, whereas removal of the meta-chloride as in
PCH6 actually resulted in more potent inhibition (IC50=2.1 nM).
Whereas repositioning the ortho-chloride of PCH1 to the para
position as in PCH7 did not affect the effect, replacing this
chloride with a methoxy group as in PCH8 gave poorer inhibition
(IC50=1.6 mM), indicating that electron-donating and/or steric
properties are detrimental at this position. Combinations of
modifications to the pyridine and chlorophenyl rings in PCH9
and PCH10 resulted in decreased efficacy; however, comparison
of PCH10 to the other meta-pyridine derivative PCH2 again
indicates that improved inhibition results from removal of the meta-
chloride substituent, as was observed with PCH1 and PCH6.
Chemical variations of NT1 maintained the 2-nitrotriazole
moiety of the parent while containing modifications in the linker,
nitrophenyl and trifluorotoluyl groups (Fig. 8). These modifications
include the removal of the latter aromatic ring as in NT2 or
replacement with a pyridine ring as in NT3, reintroduction of a
substituent meta to the oxygen (NT4), removal of the nitrophenyl
ring as in NT5 or introduction of another electron-withdrawing
substituent as in NT6 and NT7 or increasing the linker length
between the nitrotriazole and carboxamide group and placing the
trifluoromethyl group of NT8 at the ortho ring position as in NT9.
The IC50 values obtained for the modified compounds were all
similar, suggesting that a variety of substituents are tolerated.
To explore the importance of the additional substituents and of
the positioning of the two aromatic rings of CX1, analogues
CX2–CX6 were assayed for growth inhibition as well (Fig. 8).
Truncation of the alkyl linker from six to five or four carbons in
CX2 and CX3, respectively, revealed a preference for the pentyl
linker, yielding an IC50 of 2.5 nM. However, the butyl linker in
CX3 also gave IC50 lower than the parent compound CX1
(5.16 nM versus 23 nM). When the positioning of the methyl
groups on the chloroxylenol group of CX1 was modified as in
CX4, the effect was adversely affected, raising the IC50 to
300 nM. However, variation in the linker length as in CX5 and
CX6 again revealed a similar pattern of preference, as the pentyl
linked CX5 also displayed the most potency among the 4-chloro-
2,6-xylenol series, with an IC50 of 20.5 nM.
Discussion
New compounds are desperately needed to fight efficiently T.
cruzi, the parasite responsible for Chagas disease. To this aim, we
optimized a simple and straight-forward assay that allows the HTS
of compounds against T. cruzi replicating within mammalian cells.
We tested 2000 compounds from the DIVERSet chemical library.
Figure 5. PCH1 and NT1 inhibit intracellular replication of b-gal T. cruzi. A. PCH1;B .NT1. Cells were incubated with T. cruzi trypomastigotes
for 2 h, after which compounds were added at indicated concentrations and incubated for 2 days. Parasites were stained and the number of
parasites per infected cell was counted. 200–300 cells/well were scored. Data represents the average values6standard deviation obtained from
triplicate wells of a representative experiment out of three.
doi:10.1371/journal.pntd.0000384.g005
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matrix metalloproteinase-9 in a whole cell assay [20] and to find
inhibitors of the ribonucleic activity of angiogenin using a cell-free
system [21]. However, to our knowledge this is the first time this
library has been used to discover new anti-microbials.
After screening the 2000 compounds, 70 confirmed hits (3.5%)
were obtained. The rate of hits was relatively high, probably due to
two main reasons: (1) the high concentration of compounds used for
primary screening (25 mg/ml) and (2) because any compounds that
are toxic to mammalian cells would also be scored as hits in this
experimental design, since they would affect the host cells that are
required for parasite replication. After a secondary screening to
eliminate these false positive hits and select the most effective
compounds, three potential candidates (0.15% of all compounds)
were identified that were active in the nanomolar range at the stage
of intracellular replication of the T. cruzi parasites.
The three hits we selected had IC50 values in the low-
nanomolar range and low toxicity on mammalian cells. Although
HepG2 cells have a limited drug metabolism activity to assess
toxicity of metabolites [22], they are a useful model as a primary
toxicity screen due to their human origin and ease of use [18].
Interestingly, although the selected hits had IC50 values in the low-
nanomolar range when tested on intracellular replication of
parasites, they were only active on free trypomastigotes at higher
concentrations that were similar to or above the TC50 on
mammalian cells. Therefore, it appears that our screening assay
favors the selection of drugs that are effective against intracellular
replication of parasites but not active on free trypomastigotes. This
is probably a consequence of adding compounds and trypomas-
tigotes simultaneously to host cells, a procedure that would not
allow enough time for compounds with activity against free
trypomastigotes to prevent completely invasion of host cells.
Oneofthecompoundsthatwehaveinvestigated,NT1,hasanIC50
of190 nMontheb-galT.cruzistrain.NT1alsodisplayedactivityonthe
Ystrain,butathigherconcentrations.Interestingly,whentestedagainst
L.majorandL.amazonensisNT1hadadose-dependantanti-leishmanial
effectontheintracellularformoftheparasites.NTIwaspotentagainst
L. major and L. amazonensis with an estimated IC50 of ,500 nM.
This compound inhibited T. cruzi amastigote replication within
host cells, but we did not observe amastigote lysis at 2–3 days. Its
effect might therefore be more trypanostatic than trypanocidal.
The toxicity of NT1 on mammalian cells was between 40- and
159-fold depending on the type of mammalian cells and the
duration of the cytotoxicity assay. This is a relatively high toxicity
and might therefore be an issue for further development of this
compound.
Figure 6. PCH1 and NT1 inhibit intracellular replication of T. cruzi Y strain. A. PCH1;B .NT1. Cells were incubated with Y strain
trypomastigotes for 2 h, after which compounds were added and incubated for 2 days. Parasites were stained and the number of parasites per
infected cell was counted. 200–300 cells/well were scored. Data represents the average values6standard deviation obtained from triplicate wells of a
representative experiment out of two.
doi:10.1371/journal.pntd.0000384.g006
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acetamide group linked to a nitro-substituted, heteroaromatic five-
membered ring (triazole and imidazole, respectively). NT1 is also
chemically related to the approved anti-fungal agent fluconazole, as
it contains a triazole ring, of which fluconazole hastwo. Fluconazole
has an IC50 against T. cruzi in vitro of 8 mM [7,23], but its activity in
mice models of T. cruzi infection has not been confirmed [24].
Moreover, fluconazole has been used with some success against
cutaneous leishmaniasis caused by L. major, although some
geographically distinct species such as L. tropica are refractory.
Upon testing of chemical analogues of NT1 that preserve the
nitrotriazole moiety but include a variety of aryl and aryl ether
substituents, we found that these variations did not modify strongly
the anti-trypanosomal effect. It is therefore likely that the
pharmacophore is the nitrotriazole group acting through a non-
targeted mechanism, like BZN.
Another compound identified in the initial screen, CX1,
possesses imidazole and phenyl rings, similar to BZN but without
a nitro substituent on the imidazole group and with chloride and
methyl groups on the phenyl ring (i.e., 4-chloro-3,5-xylenol). It is
not clear whether CX1 and BZN share the same target in T. cruzi.
Comparison of the anti-T. cruzi activity of CX1 and BZN side by
side revealed that the IC50 of CX1 is 50 times lower than that of
BZN (23 nM versus 1.15 mM). CX1’s dose effect on the Y strain
of T. cruzi was similar to the b-gal-expressing Tulahuen strain,
suggesting that the IC50 is close for the two strains. Additionally,
intracellular L. major and L. amazonensis are sensitive CX1. Indeed,
it significantly reduced the L. major and L. amazonensis parasite
burden by 70% at a concentration of 2 mM, and had estimated
IC50 of ,500 nM against both pathogens.
Numerous studies have been performed trying to modify
imidazole derivatives to decrease their toxicity profile, which, for
compounds such as BZN, is the cause of severe side effects when
used for treatment in patients [25]. The toxicity of CX1 in vitro was
over 500-fold greater than the IC50 suggesting that this compound
may be developed into a therapeutic drug. However, as CX1 is an
amphiphilic compound, its cardiotoxicity will need to be evaluated
carefully [26]. Additionally, this compound induced effective lysis
of intracellular amastigotes, showing a strong trypanocidal activity.
While trypanostatic drugs, such as NT1, may be more effective
against the acute phase of disease, where parasites replicate
rapidly, inducing lysis like CX1 does might be essential for the
development of drugs against the chronic stage of Chagas disease,
where parasites are found in a quiescent intracellular state.
Figure 7. Intracellular Leishmania are sensitive to PCH1, NT1 and CX1. Bone marrow-derived macrophages were infected with either L. major
(A) or L. amazonensis (B) parasites at a multiplicity of infection of 3:1 for 2 h, before addition of the different compounds at the indicated
concentrations. Infected macrophages were incubated for 5 (A) or 3 days (B), before the preparations were stained with DAPI and the number of
parasite nuclei was counted. AMB, Amphotericin B. Data represents the average values obtained from triplicate wells of a representative experiment
out of two.
doi:10.1371/journal.pntd.0000384.g007
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bridges a pyridine ring on the carbonyl side and furan and
chlorophenyl rings on the nitrogen end. We observed that the
position of the nitrogen inortho withinthering iscrucialfor theeffect,
aswellasthe removal of themeta-chloridesubstituent.The hydrazide
compound PCH1 induced major changes in amastigote morphol-
ogy, such as presence of larger amastigotes in which replication of
DNA-containing organelles took place, but normal cytokinesis into
daughter cells was abnormal. Several compounds that affect
epimastigotes replication, such as the vinca alkaloids agents
vincristine and vinblastine present a similar phenotype, with
formation of giant cells containing multiple nuclei and kinetoplasts
[27]. The microtubule stabilizing agent taxol also inhibits cell
division, but, unlike treatment with PCH1, the parasites retain a
normal nucleus/kinetoplast relationship [28]. At higher doses,
PCH1 however had a trypanolytic effect. Moreover, PCH1 was
found to have a deleterious effect on intracellular L. major with an
estimated IC50 of ,2 mM and was more potent against L.
amazonensis, which replicates in a large communal phagolysosome,
with an estimated IC50 of ,100 nM. As hydrazide groups are
problematic in a compound because of the possibility of release
causingtoxicity[29],attemptstoreplacethisgroupwithabioisostere
should be made during chemical optimization.
In conclusion, HTS assays are a good tool to identify new
compounds with anti-kinetoplastid activity. In this study, we
found three new compounds, all possessing hydrophobic groups
including multiple aromatic rings, at least one of which being
nitrogen-substituted. It is apparent that the most important feature
of the three highly effective compounds is the presence of
hydrophobic, aromatic moieties. However, it is further apparent
that electronic effects also serve a critical role. Despite the chemical
similarities observed, the different phenotypic changes induced by
each compound suggest that they are affecting different pathways in
the intracellular parasites. As we have demonstrated their efficacy in
vitro, it is now critical to determine their toxicity in animals and their
efficacy in vivo to assess their potential as therapeutic agents against
Chagas disease and leishmaniasis.
Supporting Information
Alternative Language Abstract S1 Translation of the Abstract
into Spanish by Ana Rodriguez
Found at: doi:10.1371/journal.pntd.0000384.s001 (0.04 MB
DOC)
Figure S1
Found at: doi:10.1371/journal.pntd.0000384.s002 (0.11 MB XLS)
Figure 8. Inhibition of T. cruzi growth by PCH1, NT1, CX1 and their derivatives. Each compound was tested for T. cruzi growth inhibition to
determine IC50 values. Data are displayed as mean6standard deviation of three independent experiments.
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